NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis

FRA:NOV • DK0062498333

41.67 EUR
+0.96 (+2.36%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

NOV gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. NOV has an excellent profitability rating, but there are concerns on its financial health. NOV is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year NOV was profitable.
  • In the past year NOV had a positive cash flow from operations.
  • Each year in the past 5 years NOV has been profitable.
  • In the past 5 years NOV always reported a positive cash flow from operatings.
NOV.DE Yearly Net Income VS EBIT VS OCF VS FCFNOV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

1.2 Ratios

  • With an excellent Return On Assets value of 18.87%, NOV belongs to the best of the industry, outperforming 98.18% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 52.79%, NOV belongs to the top of the industry, outperforming 94.55% of the companies in the same industry.
  • NOV has a better Return On Invested Capital (30.79%) than 98.18% of its industry peers.
  • NOV had an Average Return On Invested Capital over the past 3 years of 43.61%. This is significantly above the industry average of 14.38%.
  • The last Return On Invested Capital (30.79%) for NOV is well below the 3 year average (43.61%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROIC 30.79%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
NOV.DE Yearly ROA, ROE, ROICNOV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • The Profit Margin of NOV (33.14%) is better than 100.00% of its industry peers.
  • In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
  • NOV's Operating Margin of 41.30% is amongst the best of the industry. NOV outperforms 94.55% of its industry peers.
  • NOV's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of NOV (80.98%) is better than 83.64% of its industry peers.
  • NOV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
NOV.DE Yearly Profit, Operating, Gross MarginsNOV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
  • NOV has about the same amout of shares outstanding than it did 1 year ago.
  • NOV has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for NOV is higher compared to a year ago.
NOV.DE Yearly Shares OutstandingNOV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
NOV.DE Yearly Total Debt VS Total AssetsNOV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B 500B

2.2 Solvency

  • NOV has an Altman-Z score of 4.13. This indicates that NOV is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.13, NOV is in line with its industry, outperforming 56.36% of the companies in the same industry.
  • NOV has a debt to FCF ratio of 4.52. This is a neutral value as NOV would need 4.52 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 4.52, NOV perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
  • NOV has a Debt/Equity ratio of 0.61. This is a neutral value indicating NOV is somewhat dependend on debt financing.
  • NOV has a Debt to Equity ratio (0.61) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Altman-Z 4.13
ROIC/WACC4.58
WACC6.73%
NOV.DE Yearly LT Debt VS Equity VS FCFNOV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.3 Liquidity

  • NOV has a Current Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NOV has a Current ratio of 0.80. This is amonst the worse of the industry: NOV underperforms 87.27% of its industry peers.
  • NOV has a Quick Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.57, NOV is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.57
NOV.DE Yearly Current Assets VS Current LiabilitesNOV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.77% over the past year.
  • The Earnings Per Share has been growing by 20.66% on average over the past years. This is a very strong growth
  • NOV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
  • NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.45% on average over the next years.
  • Based on estimates for the next years, NOV will show a small growth in Revenue. The Revenue will grow by 3.57% on average per year.
EPS Next Y-1.09%
EPS Next 2Y2.5%
EPS Next 3Y7.19%
EPS Next 5Y3.45%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y3.57%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NOV.DE Yearly Revenue VS EstimatesNOV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100B 200B 300B
NOV.DE Yearly EPS VS EstimatesNOV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 13.53 indicates a correct valuation of NOV.
  • NOV's Price/Earnings ratio is a bit cheaper when compared to the industry. NOV is cheaper than 74.55% of the companies in the same industry.
  • NOV is valuated rather cheaply when we compare the Price/Earnings ratio to 26.68, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 13.67, the valuation of NOV can be described as correct.
  • Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than 76.36% of the companies in the same industry.
  • NOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 13.53
Fwd PE 13.67
NOV.DE Price Earnings VS Forward Price EarningsNOV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NOV is valued a bit cheaper than 76.36% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NOV indicates a slightly more expensive valuation: NOV is more expensive than 61.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 47.75
EV/EBITDA 9.94
NOV.DE Per share dataNOV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.65
EPS Next 2Y2.5%
EPS Next 3Y7.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.82%, NOV has a reasonable but not impressive dividend return.
  • NOV's Dividend Yield is rather good when compared to the industry average which is at 1.89. NOV pays more dividend than 81.82% of the companies in the same industry.
  • NOV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 3.82%

5.2 History

  • The dividend of NOV is nicely growing with an annual growth rate of 19.05%!
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
NOV.DE Yearly Dividends per shareNOV.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • NOV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y2.5%
EPS Next 3Y7.19%
NOV.DE Yearly Income VS Free CF VS DividendNOV.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B
NOV.DE Dividend Payout.NOV.DE Dividend Payout, showing the Payout Ratio.NOV.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVO NORDISK A/S-B

FRA:NOV (2/13/2026, 7:00:00 PM)

41.67

+0.96 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)05-06
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap185.29B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts71.76
Price Target54.04 (29.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.82%
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.99%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.05%
EPS beat(4)2
Avg EPS beat(4)-0.8%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)0.97%
EPS beat(12)8
Avg EPS beat(12)1.44%
EPS beat(16)11
Avg EPS beat(16)1.65%
Revenue beat(2)1
Avg Revenue beat(2)-1.15%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)0.9%
Revenue beat(4)1
Avg Revenue beat(4)-0.96%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)0.9%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)0.5%
Revenue beat(16)9
Avg Revenue beat(16)0.83%
PT rev (1m)-1.65%
PT rev (3m)-11.88%
EPS NQ rev (1m)-10.29%
EPS NQ rev (3m)-15.71%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-11.16%
Revenue NQ rev (1m)-51.61%
Revenue NQ rev (3m)-7.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.82%
Valuation
Industry RankSector Rank
PE 13.53
Fwd PE 13.67
P/S 4.48
P/FCF 47.75
P/OCF 11.62
P/B 7.13
P/tB 21.63
EV/EBITDA 9.94
EPS(TTM)3.08
EY7.39%
EPS(NY)3.05
Fwd EY7.32%
FCF(TTM)0.87
FCFY2.09%
OCF(TTM)3.59
OCFY8.6%
SpS9.3
BVpS5.84
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.65
Graham Number20.12
Profitability
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROCE 39.01%
ROIC 30.79%
ROICexc 33.56%
ROICexgc 59.2%
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
FCFM 9.38%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Debt/EBITDA 0.79
Cap/Depr 409.94%
Cap/Sales 29.16%
Interest Coverage 37.34
Cash Conversion 79.59%
Profit Quality 28.3%
Current Ratio 0.8
Quick Ratio 0.57
Altman-Z 4.13
F-Score5
WACC6.73%
ROIC/WACC4.58
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-1.09%
EPS Next 2Y2.5%
EPS Next 3Y7.19%
EPS Next 5Y3.45%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y3.57%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year13.84%
EBIT Next 3Y11.7%
EBIT Next 5Y6.93%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%

NOVO NORDISK A/S-B / NOV.DE FAQ

What is the fundamental rating for NOV stock?

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.


Can you provide the valuation status for NOVO NORDISK A/S-B?

ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.


What is the profitability of NOV stock?

NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.


Can you provide the expected EPS growth for NOV stock?

The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -1.09% in the next year.


Is the dividend of NOVO NORDISK A/S-B sustainable?

The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.